Related Experiment Video

Updated: May 11, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis

Rachel Audo1, Bernard Combe, Michael Hahne

  • 1Institut de Génétique Moléculaire de Montpellier, CNRS, UMR 5535, Montpellier, France. rachel.audo@igmm.cnrs.fr

Cytokine
|May 9, 2013
PubMed

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for rheumatoid arthritis (RA) treatment by targeting immune cells and synovial hyperplasia. However, potential adverse effects and resistance mechanisms require further investigation for safe and effective therapeutic application.

Area of Science:

  • Immunology
  • Rheumatology
  • Molecular Biology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a TNF superfamily member known for inducing apoptosis in cancer cells.
  • TRAIL has been investigated for potential benefits in rheumatoid arthritis (RA), including controlling synovial hyperplasia and immune cell hyperactivation.
  • Recent studies suggest TRAIL may also play a disease-promoting role in RA, with adverse effects and resistance mechanisms potentially counteracting therapeutic benefits.

Purpose of the Study:

  • To review the multifaceted role of TRAIL in immune regulation within the context of RA.
  • To examine TRAIL's impact on synovial hyperplasia and joint remodeling in RA.
  • To discuss the potential therapeutic applications and challenges of using TRAIL for RA treatment.

Main Methods:

  • Literature review of studies investigating TRAIL in cancer and rheumatoid arthritis.
  • Analysis of mechanisms underlying TRAIL's pro-apoptotic and immune-modulating effects.
  • Evaluation of evidence for both beneficial and detrimental roles of TRAIL in RA pathogenesis.

Main Results:

  • TRAIL exhibits specific pro-apoptotic effects on cancer cells, leading to its consideration as an anti-cancer therapeutic.
  • In RA models, TRAIL has demonstrated potential in managing synovial hyperplasia and immune cell activity.
  • Contradictory findings indicate a potential disease-promoting role for TRAIL in RA, alongside concerns about adverse effects and resistance.

Conclusions:

  • TRAIL's role in RA is complex, with both potential therapeutic benefits and risks.
  • Understanding TRAIL's immune regulatory functions in RA is crucial for evaluating its treatment potential.
  • Further research is needed to elucidate TRAIL's precise mechanisms in RA and to optimize its therapeutic use, addressing potential adverse effects and resistance.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...